Skip to NavigationSkip to content

Business Services

Top Ten most popular articles on this week

Indian pharmaceutical firms received more than double the amount of warning letters in the first ten months of 2019, compared with 2018, while Pakistan has registered cases against 200 pharmaceutical companies as it cracks down on illict pratices.

Also in the news, a team at Cardiff University have discovered a new part of the human immune system that could be harnessed to kill prostate, breast, lung and other cancers in lab tests.

China approves Roche cancer drug Kadcyla

China has approved the import of Roche’s drug for breast cancer, just after it recently won expanded approval in the US, Canada and Europe.

The drug is an antibody-drug conjugate (ADC). Like other ADCs, it is a type of treatment that combines cancer-tracking proteins with powerful cell toxins. They are becoming more popular as a treatment as companies like Roche and GlaxoSmithKline have tested a record number of these compounds in people.

Collaborating to realise the potential of precision medicine

Published on 20/01/20 at 11:38am

Healthcare is an evolving continuum, and while traditional strategies have seen improvements to patient outcomes over time, voices in the industry have been calling ever louder for a more targeted approach over the past decade. Collaboration may just be the key to make this shift a reality, as Matt Fellows discovers.

Ipsen appoints new Exec VP and Chief Medical Officer

Published on: 17/01/20

Ipsen has named Dr Steven Hildemann as its new Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance.

In his new role, which begins on 1 March 2020 and will be based in Paris, he will report directly to Ipsen CEO Aymeric Le Chatelier. His remit will include the provision of medical strategy to the company’s scientific, clinical and business teams, while also working in tandem with its R&D operations to design and direct clinical trials efforts to generation of post-launch data.

Top Ten most popular articles on this week

Pakistan is cracking down on corruption and has registered cases against 200 pharmaceutical companies, while in the US the FDA has move to authorise Blueprint Medicines’ kinase inhibitor Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal stromal tumours.

In Europe, Sanofi has revealed that the European Commission has expanded the existing label for Toujeo to include the treatment of children and adolescent patients with diabetes.

US-China trade deal sees changes on drug patents

The US and China signed the first part of a broader trade pact that included setting up a system to resolve conflicts over drug patents between the two countries.

In a statement the Trump administration said: “Robust protection of intellectual property is critical to incentivizing the development of new and innovative treatments and cures.”

HIV infections fall by 73% in bi and gay British men

Public Health England has released figures that show that HIV rates in bi and gay men have fallen by 73% since 2014 in the UK.

This has largely been attributed to the rise in the use of pre-exposure prophylaxis (Prep). It is a pill that is taken daily, or prior to sex, to prevent HIV infection. If taken consistently it protects cells in the body and disables the virus to stop it multiplying, so it won’t spread even if a condom isn’t used during sex.

Working Life Interview: Jean-Paul Kress, CEO of MorphoSys

Published on 13/01/20 at 01:05pm

With a medical doctorate as well as degrees in pharmacology and immunology under your belt, was your path always to go into pharma even from the earliest stages of your career?

Top Ten most popular articles on this week

The US pharamaceutical industry dominates the news this week, with Pfizer, Sanofi and GlaxoSmithKline all increasing their drug prices while Novo Nordisk is offering its US patients free insulin.

Staying with America, the link between talc powder and ovarian cancer has been cast in to doubt, with the largest study of its kind concluding their is no link between them.

10. FDA gives a priority review for key heart failure drug Farxiga

WHO says Chinese pneumonia outbreak may be a new virus

The recent pneumonia outbreak in Wuhan could potentially be a new virus, according to the World Health Organisation (WHO).

The WHO said it could be an emerging member of the family of viruses that caused the SARS and MERS outbreaks.

The UN health agency said it needed more information to confirm precisely what is causing the infections.

A team of Chinese experts showed a new type of coronavirus caused the outbreak that began in December.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches